SCHEMBL4037293

SCHEMBL4037293

COc1ccc2cc(C)c(NC(=O)c3ccccc3NCc3ccnc(C#N)c3)nc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 4/20 0.51
BRAF P15056 4/20 0.51
KDR P35968 4/20 0.45
ACP1 P24666 1/20 0.43
PTPN7 P35236 1/20 0.43
PTPN12 Q05209 1/20 0.43
PTPN22 Q9Y2R2 1/20 0.43
FLT1 P17948 1/20 0.43
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 4/20 0.42
GAA P10253 3/20 0.42
CLK1 P49759 2/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 4/20 0.42
TP53 P04637 2/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4035003 0.88 KDR (0.45) KITBRAFKDRFLT1KDM4E
SCHEMBL4035005 0.87 KDR (0.45) KITBRAFKDRFLT1KDM4E
SCHEMBL4037276 0.85 KDR (0.43) KITBRAFKDRFLT1MAPT
SCHEMBL4037432 0.82 KDR (0.44) KDRFLT1KDM4EALDH1A1MAPT
SCHEMBL4037145 0.82 KDM4E (0.48) KDRFLT1KDM4EMAPTTP53
SCHEMBL4037147 0.80 KDR (0.43) KDRFLT1KDM4EALDH1A1SMN1; SMN2
SCHEMBL6542888 0.80 KDR (0.43) KDRFLT1KDM4ESMN1; SMN2MAPT
SCHEMBL4032277 0.79 KDR (0.42) KDRFLT1KDM4ESMN1; SMN2MAPT
SCHEMBL6542706 0.76 KIT (0.56) KITBRAFKDM4EALDH1A1GAA
SCHEMBL4588770 0.75 KIT (0.61) KITBRAFKDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392680-B1 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 BAYER SCHERING PHARMA AG (DE) 2009-07-22 EP disclosed
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 FLT4, KDR, FLT1 KIT 34/4885BRAF 23/4885KDR 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.